Natixis Advisors LLC Trims Holdings in Biogen Inc. $BIIB

Natixis Advisors LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB) by 15.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,336 shares of the biotechnology company’s stock after selling 6,180 shares during the period. Natixis Advisors LLC’s holdings in Biogen were worth $5,867,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC lifted its holdings in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares in the last quarter. Advisory Services Network LLC lifted its holdings in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares in the last quarter. Davis Investment Partners LLC lifted its holdings in Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares in the last quarter. Optas LLC lifted its holdings in Biogen by 4.5% in the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares in the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Biogen by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 89 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Sanford C. Bernstein dropped their price objective on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Wedbush upped their price objective on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. The Goldman Sachs Group upped their price objective on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and set a $225.00 price objective (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. Finally, Evercore assumed coverage on shares of Biogen in a research note on Friday, May 15th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average price target of $217.26.

Biogen Stock Down 1.4%

BIIB opened at $192.62 on Tuesday. The firm has a 50 day moving average price of $187.63 and a 200 day moving average price of $183.63. The company has a market cap of $28.44 billion, a PE ratio of 20.67 and a beta of 0.20. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.